Kura ziftomenib Sale Triggers $135M Kyowa-Kirin Payment
Kura Oncology, Inc. (NASDAQ: KURA) announced completion of the first US commercial sale of KOMZIFTI...
NASDAQ: KURA
Kura Oncology and Kyowa Kirin Ink Licensing Deal for Menin Inhibitor Ziftomenib
US-based Kura Oncology, Inc. (NASDAQ: KURA) has entered into a licensing deal with Japan-headquartered Kyowa...